bioAffinity Technologies' CyPath Lung Test Shows Potential Significant Healthcare Savings By Reducing Unnecessary Follow-Up, Medical Complications And Overdiagnosis In Peer-Reviewed Study
Portfolio Pulse from Benzinga Newsdesk
bioAffinity Technologies' CyPath Lung test could save significant healthcare costs by reducing unnecessary follow-ups and complications in lung cancer detection, as per a peer-reviewed study. The test could have saved $379 million in 2022 for Medicare patients.
September 18, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
bioAffinity Technologies' CyPath Lung test demonstrates potential for significant cost savings in lung cancer detection, potentially saving $379 million in 2022 for Medicare patients by reducing unnecessary follow-ups and complications.
The study highlights the economic benefits of bioAffinity's CyPath Lung test, suggesting it could significantly reduce healthcare costs by minimizing unnecessary procedures. This positive economic impact could boost investor confidence and potentially increase the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100